TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8106774
Drug: Hevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hevac B vaccine (H), after booster at month 12
Study: 2698453
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fluspirilene
Study: 2698453
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg fluspirilene
Study: 2698453
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg fluspirilene
Study: 4549500
Drug: Monovalent acetone‐inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent acetone‐inactivated typhoid vaccine by jet injection
Study: 4549500
Drug: Heat‐killed TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat‐killed TAB by jet injection
Study: 4549500
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (monovalent acetone‐inactivated typhoid vaccine and heat‐killed TAB)
Study: 4549500
Drug: Second jet
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second jet injection 5 weeks after the first
Study: 29231496
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with auricular point sticking therapy
Study: 29231496
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (20 mg paroxetine hydrochloride once a day for 8 weeks)
Study: 24590412
Drug: Family-centered, school-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-centered, school-based intervention including a 13-week behavioral parenting intervention and concurrent group for children.
Study: 21365053
Drug: Prosthetic abutments
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosthetic abutments with a Morse taper connection and a platform switch (test group)
Study: 12640530
Drug: 48-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-week group (6 MU of natural IFN-alpha by intramuscular injection three times weekly for 24 weeks)
Study: 12640530
Drug: 72-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72-week group (6 MU of natural IFN-alpha by intramuscular injection three times weekly for 48 weeks)
Study: 10598606
Drug: Succinylcholine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1.0 mg/kg)
Study: 10553857
Drug: Mivacurium (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.20 mg/kg)
Study: 2877594
Drug: Vecuronium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.08 mg/kg)
Study: 27332391
Drug: Daily teleconsultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily teleconsultation for one week between hospital-based telenurses and patients with severe COPD
Study: 22336194
Drug: Preventative physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventative physiotherapy program, carried out twice a day for three weeks (week 34, 35, 36 postmenstrual age).
Study: 7940651
Drug: Zung-12 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zung-12 administered in the morning
Study: 7940651
Drug: Zung-12 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zung-12 administered in the afternoon
Study: 2573679
Drug: Hyperbaric oxygen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen, hypoxic cell radiosensitizers, modification of the oxygen‐unloading capacity of haemoglobin, hyperthermia, bio‐reductive drugs
Study: 2573679
Drug: Hypoxic cell
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic cell radiosensitizers and other agents
Study: 31669562
Drug: Clonidine 50
Normalized name: cloNIDine 500 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 50 μg
Study: 31669562
Drug: Clonidine 100
Normalized name: cloNIDine 100 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 100 μg
Study: 12380661
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (50-100 microg/h)
Study: 19441968
Drug: Filial Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filial Therapy and Kinder Training (play-based interventions)
Study: 17868732
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg daily for 4 weeks, followed by 2 weeks off drug per treatment cycle)
Study: 11584378
Drug: Triple-antigen recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-antigen recombinant vaccine (20-microg dose)
Study: 11584378
Drug: Single-antigen vaccine
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-antigen vaccine (S only)
Study: 7864561
Drug: Naftidrofuryl (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (400 mg, 2 daily infusions for 8 days)
Study: 31978354
Drug: IIV (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV (full human dose, intramuscular)
Study: 30232107
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who understood their treatment intent
Study: 30232107
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who did not understand their treatment intent
Study: 27871601
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.1 mL/kg)
Study: 20931097
Drug: Men (perceived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men (perceived benefit from CC)
Study: 20931097
Drug: Women (perceived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women (perceived benefit from CC)
Study: 20931097
Drug: Low-risk men
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk men (perceived benefit from CC)
Study: 20931097
Drug: Low-risk women
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk women (perceived benefit from CC)
Study: 20931097
Drug: Low-risk younger
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk younger patients (perceived benefit from CC)
Study: 20931097
Drug: Low-risk older
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk older patients (perceived benefit from CC)
Study: 20931097
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who agreed to CC (perceived benefit from CC)
Study: 20931097
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who were disagreeable or made no comment (perceived benefit from CC)
Study: 18230968
Drug: Conventional yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Study: 18230968
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (100 g/day for 2 weeks)
Study: 18230968
Drug: Conventional yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yoghurt (100 g/day for 2 weeks)
Study: 18230968
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (200 g/day for 2 weeks)
Study: 18230968
Drug: Conventional yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yoghurt (200 g/day for 2 weeks)
Study: 18230968
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (100 g/day for 2 weeks and 200 g/day for 2 weeks)
Study: 18230968
Drug: Conventional yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yoghurt (100 g/day for 2 weeks and 200 g/day for 2 weeks)
Study: 2515825
Drug: acebutolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (10 mg/kg)
Study: 758131
Drug: Propylthiouracil (PTU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil (PTU; 300 mg/day)
Study: 31860742
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene or scaling and root planning ± placebo or polyunsaturated fatty acids fish oil
Study: 28321995
Drug: 4% Garcinia
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Garcinia mangostana L. pericarp gel (MGA) as local drug delivery with scaling and root planing (SRP)
Study: 25787121
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel with scaling and root planing (SRP)
Study: 25795452
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg QD)
Study: 25795452
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg QD)
Study: 23442248
Drug: Live vaccine
Normalized name: rubella virus live vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live vaccine as the most recent vaccination
Study: 23442248
Drug: Inactivated vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccine as the most recent vaccination
Study: 16427389
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) at doses of 40, 80, or 160 microg/kg
Study: 11574493
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg/day for three months
Study: 9762741
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine medial branch injections
Study: 9762741
Drug: saline medial
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline medial branch injections
Study: 7909099
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) at 0.4 g/kg body weight
Study: 2439559
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1,640 patients randomized to placebo therapy)
Study: 29718329
Drug: Ridinilazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridinilazole (200 mg twice daily)
Study: 29718329
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg four times daily)
Study: 23548219
Drug: Intraumbilical vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraumbilical vein oxytocin injection (10 IU, 1 mL)
Study: 21139155
Drug: Injection with
Normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection with laboratory-prepared, amplified collagen-producing cells derived from dermal fibroblasts and suspended in autologous plasma
Study: 12699514
Drug: Heat and
Normalized name: TRACH,FILTER HEAT AND MOISTURE EXCHANGER MEDLINE #DYNJAAHME5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat and moisture exchangers (HMEs) with fresh gas flows of 1.0, 3.0, or 6.0 l min‐1
Study: 12699514
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without HMEs with fresh gas flows of 1.0, 3.0, or 6.0 l min‐1
Study: 10967613
Drug: Oral iodised
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iodised oil (1 ml Lipiodol Ultrafluide, 490 mg I)
Study: 29813111
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) within 4.5 hours after NA-CRAO
Study: 29813111
Drug: Conservative standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative standard treatment (CST) from the EAGLE trial
Study: 21246840
Drug: Blank group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank group (no therapy applied)
Study: 15196285
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (FP) 200 microg once daily
Study: 15196285
Drug: Oral loratadine
Normalized name: loratadine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loratadine (LOR) 10 mg once daily
Study: 3498877
Drug: Doxycycline (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (one dose a day)
Study: 3498877
Drug: Co-trimoxazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (two doses a day)
Study: 3498877
Drug: Amoxycillin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (three doses a day)
Study: 3498877
Drug: Co-trimoxazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (two doses a day) with written instruction sheet and advice
Study: 28934800
Drug: Intraarticular corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular corticosteroid injection (ICI)
Study: 19491910
Drug: Rituximab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab, a B‐cell‐depleting anti‐CD20 monoclonal antibody
Study: 11380528
Drug: Exogenous melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous melatonin (1 mg)
Study: 11380528
Drug: 1-year oral
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-year oral melatonin treatment
Study: 8250309
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anesthesia (CSA) with 2.5-5 mg of plain bupivacaine 0.5%
Study: 8250309
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anesthesia (SS) with 20 mg of plain bupivacaine 0.5%
Study: 8250309
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anesthesia (SS)
Study: 27364049
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 units IV, 5 injections spaced 12 hours apart for a total of 200,000 units)
Study: 24934544
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g DHA (22:6) and 0.6 g EPA (20:5) for 6 months
Study: 22425127
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg) and/or Tamsulosin (0.4 mg)
Study: 16521850
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g L-Carnitine L-tartrate (LCLT) daily for 4 weeks
Study: 16521850
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g placebo (P) daily for 4 weeks
Study: 16521850
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g L-Carnitine L-tartrate (LCLT)
Study: 9733448
Drug: Fludarabine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 20 mg/m2 body surface area per day for 3 consecutive days
Study: 9733448
Drug: Fludarabine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 body surface area per day for 3 consecutive days
Study: 8018458
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg four times daily
Study: 4318020
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (800 mg)
Study: 4318020
Drug: Dichloral phenazone
Normalized name: phenazocine
DrugBank: Phenazocine (DB13606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloral phenazone (1,300 mg)
Study: 4318020
Drug: Mandrax (methaqualone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandrax (methaqualone 250 mg and diphenhydramine 25 mg)
Study: 22486193
Drug: 0.2% alcohol-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% alcohol-free chlorhexidine mouthwash applied twice a day for 30 days
Study: 11332356
Drug: Antioxidants (vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (vitamins C and E) and Calcium Channel Blockers (nimodipine)
Study: 11332356
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antioxidants or calcium channel blockers)
Study: 8935814
Drug: Naturalistic discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturalistic discontinuation of clozapine in neuroleptic‐resistant patients
Study: 30834652
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow rate reduction of 100 mL/min to a minimum of 300 mL/min
Study: 29080069
Drug: 5-Aminosalicylic Acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-Aminosalicylic Acid (5-ASA) 500 mg capsules, four times daily for 6 weeks
Study: 27426231
Drug: LFCN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFCN block with 8 ml of 0.75% ropivacaine
Study: 27426231
Drug: LFCN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFCN block with 8 ml of saline
Study: 22824201
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg everolimus daily
Study: 22824201
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg everolimus daily
Study: 8205252
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of lipiodol (0.5 ml) 1-3 months before conception (Group A)
Study: 8205252
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of lipiodol (0.5 ml) during the first month of pregnancy (Group B)
Study: 8205252
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of lipiodol (0.5 ml) during the third month of pregnancy (Group C)
Study: 11139949
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 mg/day)
Study: 2252196
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% hydrocortisone cream
Study: 1090905
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy sessions led by two nurses, twice a week for 20 sessions
Study: 28229515
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy sessions
Study: 31801563
Drug: Single orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single orally administered dose of azithromycin
Study: 23025390
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of yellow mustard bran
Study: 20932157
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with GaAlAs diode laser, 808 nm wavelength, energy density of 4 J/cm² applied on days 1, 2, and 7 after periodontal treatment
Study: 20932157
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-surgical periodontal therapy without LLLT)
Study: 16926245
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) gel therapy, 50 mg/d for 6 months
Study: 15624399
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of varicocele
Study: 11701677
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patch plus oral desogestrel (300 microg/d)
Study: 11701677
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patch plus oral desogestrel (150 microg/d)
Study: 11701677
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patch plus oral desogestrel (75 microg/d)
Study: 11701677
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patch plus oral desogestrel (various doses)
Study: 9385486
Drug: Ciprofloxacin (CIP)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP) 750 mg BID for 10 days
Study: 9385486
Drug: Clarithromycin (CLR)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (CLR) 500 mg BID for 10 days
Study: 3034221
Drug: oral metyrapone
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral metyrapone tartrate
Study: 28646216
Drug: Naftopidil 75
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 75 mg once daily
Study: 23208521
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (0.125%) with fentanyl (2 µg/ml)
Study: 19568711
Drug: Artequick (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artequick (administered twice in 24 h)
Study: 19568711
Drug: Artekin (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artekin (administered 4 times in 2 days)
Study: 11882452
Drug: Transmyocardial revascularization
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmyocardial revascularization with CO(2) laser in addition to medical treatment
Study: 11882452
Drug: Continued optimal
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued optimal medical treatment